Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 24.51% is 27% above its 5-year average of 19.35%, around the middle of its 5-year range (0.00%–53.03%).
As of the fiscal period ended Tuesday, June 30, 2026. 5.21% below its 12-month average of 25.86%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 24.51%.
DEBT TO ASSETS RATIO
24.51%
DEBT TO ASSETS RATIO AVG TTM
25.86%
DEBT TO ASSETS RATIO AVG 3Y
30.60%
DEBT TO ASSETS RATIO AVG 5Y
19.35%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-5.21%
CURRENT VS 3Y AVG
-19.91%
CURRENT VS 5Y AVG
+26.71%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 849 covered companies
CURRENT VS SECTOR MEDIAN
+27135.19%
vs the sector median at left
HCW Biologics Inc.
Market Cap
$556226.00
Debt to Assets Ratio
24.51%
TTM Avg
25.86%
3Y Avg
30.60%
5Y Avg
19.35%
Market Cap
$522716.00
Debt to Assets Ratio
0.08%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$483178.00
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$389261.00
Debt to Assets Ratio
0.18%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$835349.00
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$848052.00
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$857621.00
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| HCW Biologics Inc. (HCWB) | $556226.00 | 24.51% | 25.86% | 30.60% | 19.35% |
| VivoSim Labs, Inc. (VIVS)vs › | $522716.00 | 0.08% | N/A | N/A | N/A |
| XORTX Therapeutics Inc. (XRTX)vs › | $483178.00 | 0.00% | N/A | N/A | N/A |
| CDT Equity Inc. (CDT)vs › | $675466.00 | 0.38% | N/A | N/A | N/A |
| Niki BioSolutions, Inc. (NIKI)vs › | $389261.00 | 0.18% | N/A | N/A | N/A |
| Ridgetech, Inc. (RDGT)vs › | $801745.00 | 0.00% | N/A | N/A | N/A |
| Decoy Therapeutics Inc. (DCOY)vs › | $835349.00 | 0.00% | N/A | N/A | N/A |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $848052.00 | 0.01% | N/A | N/A | N/A |
| Sunshine Biopharma, Inc. (SBFM)vs › | $857621.00 | 0.02% | N/A | N/A | N/A |
| Bone Biologics Corporation (BBLG)vs › | $859749.00 | 0.00% | N/A | N/A | N/A |
Debt/Assets
24.5%
Debt/Equity
0.88
Current Ratio
0.06
Interest Coverage
-9.0x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 24.51% |
| 2026-03-31 | 24.06% |
| 2025-12-31 | 27.77% |
| 2025-09-30 | 29.47% |
| 2025-06-30 | 23.48% |
| 2025-03-31 | 53.03% |
| 2024-12-31 | 45.28% |
| 2024-09-30 | 48.21% |
| 2024-06-30 | 37.38% |
| 2024-03-31 | 27.60% |
| 2023-12-31 | 22.11% |
| 2023-09-30 | 18.31% |
| 2023-06-30 | 16.64% |
| 2023-03-31 | 14.67% |
| 2022-12-31 | 13.69% |
| 2022-09-30 | 12.56% |
| 2022-06-30 | 0.57% |
| 2022-03-31 | 0.60% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 1.51% |
| 2020-12-31 | 3.68% |
